VCEL
Vericel Corporation
Healthcare · Biotechnology · NGM
$36.30
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$1.8B
Total market value of the company
Trailing P/E
79.70
Expensive — high growth expected
Forward P/E
40.22
Based on estimated future earnings — lower means cheaper
Rev Growth
+30.1%
Year-over-year revenue change
Profit Margin
7.3%
How much profit the company keeps from each dollar of revenue
ROE
6.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$55.00
+52% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 7 analysts covering this stock
About Vericel Corporation

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

https://www.vcel.com

Country: United States Employees: 398 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
DISTRIBUTION
Smart money appears to be selling into strength — caution
Sharpe Ratio
-0.104
Returns do not compensate for the risk — negative edge
Kelly Fraction
-0.0122
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.276
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-14.5%
Historical annualised return based on price data
Max Drawdown
-52.5%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
196
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.16
Moves slightly more than the broader market
52W High
$45.97
21% below the year high
52W Low
$28.95
25% above the year low
Avg Volume
662,504
Average daily shares traded — higher means easier to buy and sell
Short Ratio
8.4
Days it would take all short sellers to cover — higher means more crowded
Short % Float
13.5%
Elevated short interest — bears are positioned against this
Div Yield
N/A
Annual dividend as a percentage of the share price
EPS (TTM)
$0.43
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
26.68
Heavy leverage — higher financial risk if revenues decline
Current Ratio
5.18
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
4.62
Like current ratio but excludes inventory — stricter test
Gross Margin
74.8%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-11.8%
Profit from core operations before interest and tax
Free Cash Flow
$42M
Positive — the business generates more cash than it spends
Revenue (TTM)
$292M
Total revenue over the last 12 months
Net Income
$21M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
7
Target High
$70.00
Target Median
$55.00
Target Low
$42.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.